Clinical Trial Update: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Lebrikizumab in combination with topical corticosteroids for atopic dermatitis not adequately controlled with cyclosporine; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)
• Topical corticosteroids (Corticosteroid)

Snippet

Sponsor: Almirall, S.A. | Conditions: Dermatitis, Atopic, Eczema | Phase 3 | Status: COMPLETED | Results posted: 2024-11-06